神经胶质瘤相关抗原

Glioma antigen.

机构信息

Department of Neurosurgery, Keio University School of Medicine, Tokyo, Japan.

出版信息

Adv Exp Med Biol. 2012;746:77-84. doi: 10.1007/978-1-4614-3146-6_6.

Abstract

Because several antigenic peptides of human tumors that are recognized by T-lymphocytes have been identified, immune responses against cancer can now be artificially manipulated. Furthermore, since T-lymphocytes have been found to play an important role in the rejection of tumors by the host and also to have antigen-specific proliferative potentials and memory mechanisms, T-lymphocytes are thought to play a central role in cancer vaccination. Although multidisciplinary therapies have been attempted for the treatment of gliomas, the results remain unsatisfactory. For the development of new therapies against gliomas, it is required to identify tumor antigens as targets for specific immunotherapy. In this chapter, recent progress in research on glioma antigens is described.

摘要

由于已经鉴定出了几种被 T 淋巴细胞识别的人类肿瘤的抗原肽，现在可以人为地操纵针对癌症的免疫反应。此外，由于已经发现 T 淋巴细胞在宿主对肿瘤的排斥中起着重要作用，并且具有抗原特异性增殖潜力和记忆机制，因此 T 淋巴细胞被认为在癌症疫苗接种中起着核心作用。尽管针对神经胶质瘤的治疗已经尝试了多种方法，但结果仍不尽如人意。为了开发针对神经胶质瘤的新疗法，需要鉴定肿瘤抗原作为特异性免疫治疗的靶标。本章描述了神经胶质瘤抗原研究的最新进展。